LXEO Stock Summary and Trading Ideas (Lexeo Therapeutics | NASDAQ:LXEO)

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

Lexeo Therapeutics trades on the NASDAQ stock market under the symbol LXEO.

As of April 1, 2025, LXEO stock price declined to $3.13 with 537,682 million shares trading.

LXEO has a beta of 1.25, meaning it tends to be more sensitive to market movements. LXEO has a correlation of 0.03 to the broad based SPY ETF.

LXEO has a market cap of $103.91 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that LXEO belongs to (by Net Assets): IWM, VTI, VXF, IWO, IBB.

LXEO has underperformed the market in the last year with a return of -80.0%, while the SPY ETF gained +8.6%. In the last 3 month period, LXEO fell short of the market, returning -52.4%, while SPY returned -4.0%. However, in the most recent 2 weeks LXEO has outperformed the stock market by returning +0.6%, while SPY returned -0.8%.

LXEO support price is $3.18 and resistance is $3.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXEO shares will trade within this expected range on the day.